Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Palupiprant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adlai Nortye Doses First Patient in Phase II Trial of Palupiprant for Rectal Cancer
Details : AN0025 is a small molecule prostaglandin E receptor 4 antagonist, which is being in the phase II clinical trials studies for the treatment of locally advanced rectal cancer.
Product Name : AN0025
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : Palupiprant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AN2025 (buparlisib ) is an oral pan-PI3K inhibitor, It is being evaluated in combination with paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $106.1 million
Deal Type : Public Offering
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
Details : The net proceeds will fund the ongoing registrational trial for AN2025 (buparlisib), an oral pan-PI3K inhibitor that targets all class I PI3K isoforms, the milestone payments in connection with development of AN2025 and the commercial launch, if approved...
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 29, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $106.1 million
Deal Type : Public Offering
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Nucleai
Deal Size : Undisclosed
Deal Type : Partnership
Details : The collaboration aims to focus on identifying subjects that could derive benefit from AN2025 (buparlisib) treatment in metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) patients and will expand to other indications and clinical trials.
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 31, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Nucleai
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $57.5 million
Deal Type : Public Offering
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
Details : The net proceeds will fund the ongoing registrational trial for AN2025 (buparlisib), an oral pan-PI3K inhibitor that targets all class I PI3K isoforms, the milestone payments in connection with development of AN2025 and the commercial launch, if approved...
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 10, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $57.5 million
Deal Type : Public Offering
Lead Product(s) : Pelareorep,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Oncolytics Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRACELET-1, is ongoing and evaluates pelareorep-paclitaxel combination therapy both with and without a checkpoint inhibitor used in Chinese patients with advanced or metastatic breast cancer.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
October 14, 2021
Lead Product(s) : Pelareorep,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Oncolytics Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palupiprant,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First patient has been dosed in a phase 1b clinical trial (AN0025S0103) to evaluate AN0025, an investigational, potentially first in class oral EP4 antagonist, in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with locally advanced/metas...
Product Name : AN0025
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Palupiprant,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable